Every material Form 8-K Amneal Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amneal reported third-quarter 2026 net revenue of $863 million, up 10%, and Adjusted EBITDA of $207 million, up 30%, but swung to a GAAP net loss of $22 million from net income a year earlier, driven by acquisition and integration costs and a higher tax provision. The company raised its full-year 2026 revenue, Adjusted EBITDA and adjusted EPS guidance, while lowering its operating cash flow guidance, which it attributed to higher inventory levels.
Q3 2026 net revenue was $863 million, up from $785 million in Q3 2025; Adjusted EBITDA was $207 million, up 30%.
GAAP net loss attributable to Amneal was $22 million, or $(0.06) per diluted share, compared with net income of $2 million a year earlier; adjusted diluted EPS was $0.26, up 53% from $0.17.
Full-year 2026 net revenue guidance rose to $3.15 billion to $3.25 billion from $3.10 billion to $3.20 billion; Adjusted EBITDA guidance rose to $800 million to $815 million from $750 million to $780 million.
Operating cash flow guidance was lowered to $325 million to $375 million from $350 million to $400 million, reflecting working capital, including higher inventory levels.
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, paying in part with 28,942,098 newly issued Class A shares. The company also borrowed a $350 million incremental term loan, with proceeds used as part of the purchase consideration, and says the deal adds a long-term biosimilars growth pillar. The filing does not disclose financial results or the total purchase price, so the effect on earnings and the share count is not yet quantified.
Acquisition of Kashiv BioSciences, LLC closed on August 10, 2026, under a Membership Interest Purchase Agreement dated April 21, 2026
Amneal issued 28,942,098 shares of Class A Common Stock to the sellers in a private placement exempt from registration
$350 million incremental term loan made by Bank of America, N.A. under Amendment No. 4 to the Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as agent
Amneal plans to file Kashiv financial statements and pro forma information by amendment, and to register the shares for resale on Form S-3
Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, reducing the interest rate margin on its term loans by 50 basis points. The company estimates annualized cash interest savings of approximately $12 million compared with the prior agreement, based on amounts outstanding before the amendment.
Existing term loans converted into new term loans with an aggregate principal amount of $2.039 billion
A new $45.2 million term loan was incurred, with proceeds used to prepay remaining existing term loans at par
Margin reduced to 1.50% for base rate loans and 2.50% for SOFR-based loans; stated maturity remains August 1, 2032
Estimated annualized cash interest savings of approximately $12 million; no prepayment premium on a repricing after February 3, 2027
Amneal reported second-quarter 2026 net revenue of $796 million, up 10% from $725 million a year earlier, and GAAP net income attributable to the company of $58 million, up from $22 million. The company raised its full-year 2026 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, and said a July term loan repricing is expected to cut annual cash interest by about $12 million.
Q2 2026 net revenue was $796 million, up 10%; Specialty rose 17%, Affordable Medicines rose 13%, and AvKARE fell 4%.
GAAP diluted EPS was $0.18 versus $0.07 a year earlier; adjusted diluted EPS was $0.30 versus $0.25, up 20%.
Adjusted EBITDA was $206 million, up 12% from the second quarter of 2025.
2026 guidance raised: net revenue $3.10 billion to $3.20 billion (prior $3.05 billion to $3.15 billion); adjusted diluted EPS $0.96 to $1.06 (prior $0.95 to $1.05).
Amneal Pharmaceuticals reported first-quarter 2026 net revenue of $723 million, up 4% from $695 million a year earlier, and GAAP net income attributable to the company of $62 million, up from $12 million. The company affirmed the full-year 2026 guidance it raised on April 22, 2026, which calls for net revenue of $3.05 billion to $3.15 billion and adjusted diluted EPS of $0.95 to $1.05.
Q1 2026 diluted EPS was $0.19 versus $0.04 in Q1 2025; adjusted diluted EPS was $0.27, up 29%.
Adjusted EBITDA was $202 million, up 19% from $170 million in Q1 2025.
Specialty net revenue rose 23%, while AvKARE net revenue fell 4%.
Net cash used in operating activities was $26.7 million in Q1 2026, compared with $7.4 million provided in Q1 2025.
Amneal agreed on April 21, 2026 to acquire 100% of Kashiv BioSciences, LLC for $375 million in cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments and royalties. The same day, Amneal reported preliminary first quarter 2026 results showing higher revenue, net income and EPS, and raised its 2026 adjusted EBITDA and adjusted diluted EPS guidance.
Consideration: $375 million cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments; closing expected in the second half of 2026 and requires Amneal shareholder approval.
Preliminary Q1 2026 (unaudited): consolidated net revenue $723 million, up 4% from $695 million; net income $78 million versus $25 million; diluted EPS $0.19 versus $0.04.
Raised 2026 adjusted EBITDA guidance to $740 million-$770 million from $720 million-$760 million; adjusted diluted EPS to $0.95-$1.05 from $0.93-$1.03; net revenue guidance unchanged at $3.05 billion-$3.15 billion.
Acquisition agreement has an outside date of November 17, 2026, extendable to January 12, 2027 if only certain regulatory approvals remain outstanding.
Amneal Pharmaceuticals reported fourth-quarter 2025 net revenue of $814 million, up 11% from a year earlier, and GAAP net income attributable to the company of $35 million, compared with a loss of $31 million in the fourth quarter of 2024. For the full year, revenue rose 8% to $3.02 billion and adjusted diluted EPS was $0.83, and the company gave 2026 guidance of $3.05 billion to $3.15 billion in net revenue and $0.93 to $1.03 in adjusted diluted EPS, which is above 2025 results.
Q4 2025 net revenue was $814 million, up 11%, with Specialty up 38% and Affordable Medicines down 1%
Q4 2025 GAAP diluted EPS was $0.11 versus a loss of $0.10 a year earlier; adjusted diluted EPS was $0.21 versus $0.12
Full year 2025 net revenue was $3.02 billion and adjusted EBITDA was $688 million, up 10%
2026 guidance: net revenue of $3.05 billion to $3.15 billion, adjusted EBITDA of $720 million to $760 million, adjusted diluted EPS of $0.93 to $1.03
On February 2, 2026, subsidiary Amneal Pharmaceuticals LLC amended its term loan credit agreement with JPMorgan Chase Bank, N.A. as administrative agent. Existing loans were converted into new term loans of $1,960,076,527.50, and a new term loan of $134,673,472.50 was added, with proceeds used to prepay the remaining existing loans. The company estimates annualized cash interest savings of approximately $11 million, and the August 1, 2032 maturity is unchanged.
Interest margin reduced by 50 basis points to 2.00% (base rate loans) and 3.00% (SOFR-based loans)
Converted term loans totaling $1,960,076,527.50 and a new term loan of $134,673,472.50
Estimated annualized cash interest savings of approximately $11 million; maturity remains August 1, 2032
Amendment allows a repricing transaction without a prepayment premium after August 2, 2026
Amneal Pharmaceuticals said in a January 13, 2026 investor presentation filing that it expects to meet or exceed the 2025 full-year financial guidance it gave on October 30, 2025. It also estimates net leverage of about 3.6x as of December 31, 2025, down from 3.9x a year earlier. The filing reaffirms the existing guidance ranges rather than raising them, and the figures remain estimates subject to year-end close.
Guidance ranges unchanged from October 30, 2025: net revenue $3.0 billion to $3.1 billion and adjusted diluted EPS $0.75 to $0.80
Adjusted EBITDA guidance of $675 million to $685 million; operating cash flow guidance of $300 million to $330 million
Estimated net leverage of approximately 3.6x as of December 31, 2025, compared with 3.9x as of December 31, 2024
Figures are based on current estimates and remain subject to change until year- and quarter-end closing processes are complete
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amneal Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →